RXRX

Recursion Pharmaceuticals, Inc. Class A Common Stock

3.15

USD

RXRX Earnings Reports

Positive Surprise Ratio

RXRX beat 12 of 19 last estimates.

63%

Next Report

Date of Next Report

May 04, 2026

Estimate for Q1 26 (Revenue/ EPS)

$17.81M

-$0.27

Implied change from Q4 25 (Revenue/ EPS)

-49.89%

+28.57%

Implied change from Q1 25 (Revenue/ EPS)

+20.78%

-46.00%

Recursion Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue

On Feb 25, 2026, RXRX reported earnings of -0.21 USD per share (EPS) for Q4 25, beating the estimate of -0.32 USD, resulting in a 34.78% surprise. Revenue reached 35.54 million, compared to an expected 25.08 million, with a 41.71% difference. The market reacted with a +6.80% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 17.81 million USD, implying an increase of 28.57% EPS, and decrease of -49.89% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

MaxCyte, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.06

Surprise

+26.47%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

FAQ

What were Recursion Pharmaceuticals, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Recursion Pharmaceuticals, Inc. Class A Common Stock reported EPS of -$0.21, beating estimates by 34.78%, and revenue of $35.54M, 41.71% above expectations.

How did the market react to Recursion Pharmaceuticals, Inc. Class A Common Stock's Q4 2025 earnings?

The stock price moved up 6.8%, changed from $3.53 before the earnings release to $3.77 the day after.

When is Recursion Pharmaceuticals, Inc. Class A Common Stock expected to report next?

The next earning report is scheduled for May 04, 2026.

What are the forecasts for Recursion Pharmaceuticals, Inc. Class A Common Stock's next earnings report?

Based on 7 analysts, Recursion Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of -$0.27 and revenue of $17.81M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.